津药药业股份有限公司关于子公司获得药品注册证书的公告

Group 1 - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration [1] - The drug is an opioid receptor antagonist, and the company has invested approximately 4.2 million yuan in the research and development of this product [1][2] - The domestic sales of Naloxone Hydrochloride Injection were 413 million yuan in 2022 and are projected to be 535 million yuan in 2023, indicating a growth in market demand [2] Group 2 - The approval of the drug registration certificate enhances the company's formulation product portfolio and is expected to positively impact the company's performance in the domestic formulation market [3] - However, the sales timeline, scale, and future expansion of the drug in the domestic market remain uncertain due to competitive market conditions [3]